STOK Dividend: Stoke Therapeutics Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

STOK Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	205	36	8	12	0	0
Revenue Growth (YoY)	1,181%	350%	-33%	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	58	48	41	38	31	20
Research & Development	119	89	82	77	54	32
Operating Expenses	178	137	123	116	86	53
Other Non Operating Income (Expenses)	0	0	0	0	0	0
Pretax Income	41	-88	-104	-101	-85	-52
Income Tax Expense	0	--	--	--	--	--
Net Income	41	-88	-104	-101	-85	-52
Net Income Growth	-139%	-15%	3%	19%	63%	63%
Shares Outstanding (Diluted)	58.61	54	43.99	38.9	36.74	33.49
Shares Change (YoY)	5%	23%	13%	6%	10%	11%
EPS (Diluted)	0.7	-1.64	-2.37	-2.6	-2.34	-1.56
EPS Growth	-137%	-31%	-8%	11%	50%	46%
Free Cash Flow	52	-87	-82	-35	-68	-43
Free Cash Flow Per Share	0.88	-1.61	-1.86	-0.89	-1.85	-1.28
Gross Margin	--	--	--	--	--	--
Operating Margin	12.68%	-280.55%	-1,425%	-866.66%	0%	0%
Profit Margin	20%	-244.44%	-1,300%	-841.66%	0%	0%
Free Cash Flow Margin	25.36%	-241.66%	-1,025%	-291.66%	0%	0%
EBITDA	27	-99	-112	-103	-86	-53
EBITDA Margin	13.17%	-275%	-1,400%	-858.33%	0%	0%
D&A For EBITDA	1	2	2	1	0	0
EBIT	26	-101	-114	-104	-86	-53
EBIT Margin	12.68%	-280.55%	-1,425%	-866.66%	0%	0%
Effective Tax Rate	0%	--	--	--	--	--